Additionally, a broader set of 60 glioma-related targets specific to CHR was identified (Figure 6B); this gene set includes multiple multidrug resistance-associated transporters (ABCB1, ABCC1, ABCG2), cyclin-dependent kinases (CDK1, CDK6), matrix metalloproteinases (MMP2, MMP9, MMP12), inflammatory mediators (NOS2, NOX4), and genes associated with glioma stemness or progression (APP, MAPT, IGF1R, TERT). This evidence concerns the gene NOS2 and glioma.